DSM-IV codes

Miami Dolphins and Ambetter from Sunshine Health Tackle Food Insecurity to Serve 500 Meals to South Florida Families

Retrieved on: 
Friday, February 16, 2024

FT. LAUDERDALE, Fla., Feb. 16, 2024 /PRNewswire/ -- Ambetter from Sunshine Health in collaboration with the Miami Dolphins came together to address food insecurity in South Florida and distribute food to local families in need on Wednesday, Feb. 14.

Key Points: 
  • FT. LAUDERDALE, Fla., Feb. 16, 2024 /PRNewswire/ -- Ambetter from Sunshine Health in collaboration with the Miami Dolphins came together to address food insecurity in South Florida and distribute food to local families in need on Wednesday, Feb. 14.
  • "We are grateful for our longstanding partnership with Ambetter and our shared commitment to impacting the South Florida community.
  • "We know that food insecurity is associated with poor health outcomes, including higher odds of chronic disease and mental illness," said Nathan Landsbaum, CEO of Sunshine Health.
  • We are grateful to the Miami Dolphins for teaming up with us to support the South Florida community."

Herbal medicinal product: Agni casti fructusArray, C: ongoing call for scientific data

Retrieved on: 
Friday, February 16, 2024

Herbal medicinal product: Agni casti fructusArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Agni casti fructusArray, C: ongoing call for scientific data

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

Retrieved on: 
Thursday, February 15, 2024

Frédéric Cren, Chairman, Chief Executive Officer and cofounder of Inventiva, stated: “2023 has been an eventful year for the company.

Key Points: 
  • Frédéric Cren, Chairman, Chief Executive Officer and cofounder of Inventiva, stated: “2023 has been an eventful year for the company.
  • This allowed us to draw down the second tranche of €25 million of the €50 million EIB loan in January 2024.
  • We have advanced our pivotal NATiV3 Phase III clinical trial with lanifibranor in NASH after the implementation of the revised study design in early 2023, with 913 patients randomized to date.
  • An adverse event of elevated aminotransferases has been reported in a patient enrolled in the trial following a scheduled visit.

Encompass Health announces preliminary plans to build a 60-bed inpatient rehabilitation hospital in Avondale, Arizona

Retrieved on: 
Thursday, February 15, 2024

BIRMINGHAM, Ala., Feb. 15, 2024 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced preliminary plans to build a freestanding, 60-bed inpatient rehabilitation hospital in Avondale, Arizona.

Key Points: 
  • BIRMINGHAM, Ala., Feb. 15, 2024 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced preliminary plans to build a freestanding, 60-bed inpatient rehabilitation hospital in Avondale, Arizona.
  • The hospital will be located within The District at Crystal Springs development at the southwest corner of Avondale Boulevard and McDowell Road.
  • "We are excited to bring much-needed inpatient rehabilitation services to Maricopa County," said Kim Steward, president of Encompass Health's West region.
  • The hospital will be part of Encompass Health's national network of rehabilitation hospitals, and it will be Encompass Health's seventh hospital in Arizona.

Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 15, 2024

Net product sales for the fourth quarter of 2023 were $39.9 million, compared to $25.8 million for the same period in 2022.

Key Points: 
  • Net product sales for the fourth quarter of 2023 were $39.9 million, compared to $25.8 million for the same period in 2022.
  • Research and development (R&D) expenses for the fourth quarter of 2023 were $59.7 million, compared to $58.1 million for the same period in 2022.
  • Total other income, net, for the fourth quarter of 2023 was $5.7 million, compared to $1.1 million for the same period in 2022.
  • ET to discuss company updates as well as fourth quarter and full year 2023 financial results.

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs

Retrieved on: 
Thursday, February 15, 2024

DALLAS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today provided an update on its deprioritized pipeline programs as part of an ongoing effort to help support their further potential development.

Key Points: 
  • DALLAS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today provided an update on its deprioritized pipeline programs as part of an ongoing effort to help support their further potential development.
  • Taysha has been working to find ways to advance its deprioritized programs.
  • On November 13, 2023, Taysha terminated its existing loan and security agreement and entered into a new loan and security agreement that provides consent to allow the Company to transfer intellectual property (IP) for several deprioritized programs to third parties in a more efficient manner.
  • “Today’s announcement demonstrates meaningful progress to advance important development work for several deprioritized programs.

UT Health San Antonio doctors among first to implant rechargeable deep brain stimulation device

Retrieved on: 
Thursday, February 15, 2024

SAN ANTONIO, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Doctors at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) are among the nation's first to implant a newly approved sensing rechargeable deep brain stimulation device with a 15-year battery life allowing more continual treatment of patients with movement disorders.

Key Points: 
  • SAN ANTONIO, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Doctors at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) are among the nation's first to implant a newly approved sensing rechargeable deep brain stimulation device with a 15-year battery life allowing more continual treatment of patients with movement disorders.
  • Deep brain stimulation, known as DBS, is the placement of electrodes in the brain connected to a battery-operated generator in the chest similar to a cardiac pacemaker.
  • Note: Neither UT Health San Antonio nor University Health endorses commercial products or services by name.
  • The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver of San Antonio's $44.1 billion health care and biosciences sector, is the largest academic research institution in South Texas with an annual research portfolio of $413 million.

Poxel Reports Cash and Revenue for the Full Year 2023 and Provides Corporate Update

Retrieved on: 
Thursday, February 15, 2024

Thomas Kuhn, Chief Executive Officer of Poxel, stated: “We remain focused and continue to concentrate all our efforts at securing financing options, prioritizing non-dilutive solution, and partnerships.

Key Points: 
  • Thomas Kuhn, Chief Executive Officer of Poxel, stated: “We remain focused and continue to concentrate all our efforts at securing financing options, prioritizing non-dilutive solution, and partnerships.
  • We’ve also progressed our advanced discussions – in some cases on an exclusive basis – with several potential partners for each of our three proprietary products.
  • Based on this conservative assumption, Poxel expects to receive 8% royalties on TWYMEEG® net sales.
  • As of December 31, 2023, total cash and cash equivalents were EUR 2.3 million (USD 2.6 million)1, as compared to EUR 13.1 million (USD 14.0 million) as of December 31, 2022.

Labroots Announces Agenda for its 7th Annual Drug Discovery & Development Virtual Event on February 21, 2024

Retrieved on: 
Thursday, February 15, 2024

YORBA LINDA, Calif., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual event in the Drug Discovery & Development Virtual Event Series. Hosted on February 21st and free to attend, attendees will experience the forefront of pharmaceutical innovation joining industry and academic leaders from around the world debating the latest, insightful scientific breakthroughs in this ever-evolving field.

Key Points: 
  • Focusing from pre-clinical development to clinical development, advances in the field of drug discovery and development will be explored shaping current and future challenges in drug research
    YORBA LINDA, Calif., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual event in the Drug Discovery & Development Virtual Event Series .
  • The 2024 informative agenda covers a range of sessions spanning areas including Emerging Modalities in Drug Discovery and Preclinical Development, New Methods in Pharmacogenomics, and Biomarker Applications.
  • Use the hashtag #LRdrug to follow the conversation and connect with other members of the global Drug Discovery & Development community!
  • Follow @DrugDiscoveryLR on Twitter and @DrugDiscoveryandDevelopment on Facebook to connect with our specialist Drug Discovery & Development writers and stay up to date with the latest Trending News in Drug Discovery & Development.

Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters

Retrieved on: 
Thursday, February 15, 2024

BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced a publication describing the discovery and initial development of CVN766 in the peer-reviewed journal, Bioorganic & Medicinal Chemistry Letters.

Key Points: 
  • BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced a publication describing the discovery and initial development of CVN766 in the peer-reviewed journal, Bioorganic & Medicinal Chemistry Letters.
  • In the publication titled, “Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist,” the authors describe the development of CVN766 to be over 1,000-fold more selective for the orexin 1 receptor (Ox1R) than the orexin 2 receptor (Ox2R).
  • Dysfunction of this target, Ox1R, is implicated in psychiatric disorders, such as schizophrenia, addictions (including food), and anxieties.
  • “CVN766 has demonstrated high brain permeability, prolonged receptor occupancy, and a pharmacokinetic and safety profile suitable for clinical evaluation across various psychiatric indications,” said Mark Carlton, Ph.D., chief scientific officer for Cerevance.